{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Event&page=21", "query": { "intervention": "Event", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 2909, "total_pages": 291, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Event&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Event&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-01T12:57:30.304Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05159557", "title": "In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment: Wearables", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Dementia", "Mild Cognitive Impairment", "Alzheimer Disease" ], "interventions": [ { "name": "In-Home Technology System", "type": "DEVICE" }, { "name": "Limited In-Home Technology", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of California, Berkeley", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2022-08-22", "completion_date": "2024-03-25", "has_results": true, "last_update_posted_date": "2025-09-17", "last_synced_at": "2026-11-01T12:57:30.304Z", "location_count": 1, "location_summary": "Berkeley, California", "locations": [ { "city": "Berkeley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05159557" }, { "nct_id": "NCT07744919", "title": "Severe Hepatitis Intervention With Emapalumab for Liver Disease", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis" ], "interventions": [ { "name": "Emapalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Healthcare of Atlanta", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 28, "start_date": "2026-09-01", "completion_date": "2032-09", "has_results": false, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-11-01T12:57:30.304Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07744919" }, { "nct_id": "NCT05007106", "title": "MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Uterine Cervical Neoplasms", "Endometrial Neoplasms", "Squamous Cell Carcinoma of Head and Neck", "Gallbladder Neoplasms", "Cholangiocarcinoma", "Esophageal Neoplasms", "Triple Negative Breast Neoplasms", "Hepatocellular Carcinoma", "Urinary Bladder Neoplasms", "Ovarian Neoplasms", "Stomach Neoplasms" ], "interventions": [ { "name": "Pembrolizumab/Vibostolimab Co-Formulation", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 611, "start_date": "2021-09-16", "completion_date": "2025-08-05", "has_results": true, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-11-01T12:57:30.304Z", "location_count": 14, "location_summary": "Anchorage, Alaska • Duarte, California • Orange, California + 11 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Basking Ridge", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05007106" }, { "nct_id": "NCT01031953", "title": "Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breakthrough Nausea and Vomiting", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "fosaprepitant dimeglumine", "type": "DRUG" }, { "name": "systemic chemotherapy", "type": "DRUG" }, { "name": "survey administration", "type": "OTHER" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 34, "start_date": "2008-08", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-11-01T12:57:30.304Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01031953" }, { "nct_id": "NCT04489095", "title": "Conduction Disease After Transcatheter Aortic Valve Replacement", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Aortic Stenosis", "Heart Block", "Aortic Insufficiency" ], "interventions": [ { "name": "Electrophysiology Study", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Henry Ford Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 126, "start_date": "2020-07-16", "completion_date": "2022-08-01", "has_results": false, "last_update_posted_date": "2022-12-14", "last_synced_at": "2026-11-01T12:57:30.304Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04489095" }, { "nct_id": "NCT00023244", "title": "Steroid Withdrawal in Pediatric Kidney Transplant Recipients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "End-Stage Renal Disease" ], "interventions": [ { "name": "Basiliximab", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Bactrim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "20 Years", "sex": "ALL", "summary": "1 Day to 20 Years" }, "enrollment_count": 274, "start_date": "2001-01", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2016-10-21", "last_synced_at": "2026-11-01T12:57:30.304Z", "location_count": 18, "location_summary": "Birmingham, Alabama • San Diego, California • Aurora, Colorado + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00023244" }, { "nct_id": "NCT00753636", "title": "Parkinson's Disease Isradipine Safety Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Parkinson's Disease" ], "interventions": [ { "name": "Dynacirc CR (Isradipine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "30 Years to 75 Years" }, "enrollment_count": 31, "start_date": "2008-04", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2021-11-15", "last_synced_at": "2026-11-01T12:57:30.304Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00753636" }, { "nct_id": "NCT04236284", "title": "Management of Chronic Pain and PTSD in Gulf War Veterans With tDCS+Prolonged Exposure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Pain", "PTSD" ], "interventions": [ { "name": "Home-based tDCS", "type": "DEVICE" }, { "name": "Prolonged Exposure Therapy", "type": "BEHAVIORAL" } ], "intervention_types": [ "DEVICE", "BEHAVIORAL" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2020-01-15", "completion_date": "2021-11-23", "has_results": true, "last_update_posted_date": "2023-02-03", "last_synced_at": "2026-11-01T12:57:30.304Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04236284" }, { "nct_id": "NCT01230684", "title": "Contrast Enhanced Ultrasound vs. Computed Tomographic Angiography in the Detection of Endoleaks Following AAA Repair", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Endograft Implantation to Repair Abdominal Aortic Aneurysm" ], "interventions": [ { "name": "Contrast Enhanced Ultrasound (Contrast Agent: OptisonTM)", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2010-12", "completion_date": "2011-11", "has_results": false, "last_update_posted_date": "2017-10-26", "last_synced_at": "2026-11-01T12:57:30.304Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01230684" }, { "nct_id": "NCT02504216", "title": "Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Peripheral Artery Disease" ], "interventions": [ { "name": "Rivaroxaban (Xarelto, BAY59-7939)", "type": "DRUG" }, { "name": "Rivaroxaban-Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 6564, "start_date": "2015-08-18", "completion_date": "2020-01-09", "has_results": true, "last_update_posted_date": "2020-12-08", "last_synced_at": "2026-11-01T12:57:30.304Z", "location_count": 105, "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 91 more", "locations": [ { "city": "Alexander City", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Fort Payne", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Avondale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02504216" } ] }